Nicotinamide mononucleotide, a key NAD+ precursor, treats the pathophysiology of diet- and age-induced diabetes

Inhibiting Monoacylglycerol Acyltransferase 1 Ameliorates Hepatic Metabolic Abnormalities, but not Inflammation and Injury in Mice

The effects of moderate weight gain in adipose tissue gene expression in metabolically-normal (MNO) and metabolically-abnormal (MAO) subjects

The effect of n-3 PUFA therapy on skeletal muscle gene expression profile

The effect of progressive weight loss on metabolic function

High-protein intake eliminates the weight loss-induced improvement in insulin sensitivity

CD36 deficiency causes intestinal extracellular matrix disruption and chronic neutrophil

Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice

Slc12a8 is a nicotinamide mononucleotide transporter that counteracts aging

Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice

Inhibition of Grb14, a negative modulator of insulin signaling, improves glucose homeostasis without causing cardiac dysfunction

A Critical Role of Hepatic GABA in The Metabolic Dysfunction and Hyperphagia of Obesity

Adipocyte-specific inactivation of NAMPT, a key NAD+ biosynthetic enzyme, causes a metabolically-unhealthy lean phenotype in female mice during aging

Decreased adipose tissue oxygenation is associated with insulin resistance in people with obesity

Adipose tissue immunology, inflammation and exosomes in regulating insulin sensitivity in people with obesity and nonalcoholic fatty liver disease

Removal of visceral adipose tissue prevents obesity-induced multi-organ insulin resistance, dyslipidemia, and NAFLD in mice

Nicotinamide mononucleotide increases muscle insulin sensitivity in women with prediabetes

The importance of adipose tissue NAD+ biology in regulating metabolic flexibility.

Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease

Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes